CN108939048A - Nuclear receptor ROR α is preparing the application in heart failure resistance drug - Google Patents
Nuclear receptor ROR α is preparing the application in heart failure resistance drug Download PDFInfo
- Publication number
- CN108939048A CN108939048A CN201810909723.1A CN201810909723A CN108939048A CN 108939048 A CN108939048 A CN 108939048A CN 201810909723 A CN201810909723 A CN 201810909723A CN 108939048 A CN108939048 A CN 108939048A
- Authority
- CN
- China
- Prior art keywords
- ror
- nuclear receptor
- heart failure
- ser
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091008731 RAR-related orphan receptors α Proteins 0.000 title claims abstract description 35
- 206010019280 Heart failures Diseases 0.000 title claims abstract description 27
- 229940079593 drug Drugs 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 title claims abstract description 10
- 102100039614 Nuclear receptor ROR-alpha Human genes 0.000 title claims abstract 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 108091008680 RAR-related orphan receptors Proteins 0.000 abstract description 60
- 230000000747 cardiac effect Effects 0.000 abstract description 18
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract description 16
- 108090000623 proteins and genes Proteins 0.000 abstract description 13
- 230000002107 myocardial effect Effects 0.000 abstract description 6
- 230000003387 muscular Effects 0.000 abstract description 5
- 208000006029 Cardiomegaly Diseases 0.000 abstract description 3
- 206010016654 Fibrosis Diseases 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 230000004761 fibrosis Effects 0.000 abstract description 2
- 230000006698 induction Effects 0.000 abstract 1
- 102000001620 Member 1 Group F Nuclear Receptor Subfamily 1 Human genes 0.000 description 24
- 102000019197 Superoxide Dismutase Human genes 0.000 description 13
- 108010012715 Superoxide dismutase Proteins 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000002103 transcriptional effect Effects 0.000 description 8
- 230000036542 oxidative stress Effects 0.000 description 7
- GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 210000004413 cardiac myocyte Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 102000006255 nuclear receptors Human genes 0.000 description 5
- 108020004017 nuclear receptors Proteins 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000001467 acupuncture Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- PKVWNYGXMNWJSI-CIUDSAMLSA-N Gln-Gln-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKVWNYGXMNWJSI-CIUDSAMLSA-N 0.000 description 2
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- KAFOIVJDVSZUMD-DCAQKATOSA-N Leu-Gln-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-DCAQKATOSA-N 0.000 description 2
- KAFOIVJDVSZUMD-UHFFFAOYSA-N Leu-Gln-Gln Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-UHFFFAOYSA-N 0.000 description 2
- WTZUSCUIVPVCRH-SRVKXCTJSA-N Lys-Gln-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N WTZUSCUIVPVCRH-SRVKXCTJSA-N 0.000 description 2
- 108010029290 Member 1 Group F Nuclear Receptor Subfamily 1 Proteins 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- UFKPDBLKLOBMRH-XHNCKOQMSA-N Ser-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)N)C(=O)O UFKPDBLKLOBMRH-XHNCKOQMSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 2
- 108010005233 alanylglutamic acid Proteins 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 108010047857 aspartylglycine Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000001427 coherent effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 1
- LWUWMHIOBPTZBA-DCAQKATOSA-N Ala-Arg-Lys Chemical compound NC(=N)NCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O LWUWMHIOBPTZBA-DCAQKATOSA-N 0.000 description 1
- NHCPCLJZRSIDHS-ZLUOBGJFSA-N Ala-Asp-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O NHCPCLJZRSIDHS-ZLUOBGJFSA-N 0.000 description 1
- GSHKMNKPMLXSQW-KBIXCLLPSA-N Ala-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C)N GSHKMNKPMLXSQW-KBIXCLLPSA-N 0.000 description 1
- RZZMZYZXNJRPOJ-BJDJZHNGSA-N Ala-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](C)N RZZMZYZXNJRPOJ-BJDJZHNGSA-N 0.000 description 1
- QQACQIHVWCVBBR-GVARAGBVSA-N Ala-Ile-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QQACQIHVWCVBBR-GVARAGBVSA-N 0.000 description 1
- SUMYEVXWCAYLLJ-GUBZILKMSA-N Ala-Leu-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O SUMYEVXWCAYLLJ-GUBZILKMSA-N 0.000 description 1
- WEZNQZHACPSMEF-QEJZJMRPSA-N Ala-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 WEZNQZHACPSMEF-QEJZJMRPSA-N 0.000 description 1
- IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 1
- FQNILRVJOJBFFC-FXQIFTODSA-N Ala-Pro-Asp Chemical compound C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N FQNILRVJOJBFFC-FXQIFTODSA-N 0.000 description 1
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 1
- VHAQSYHSDKERBS-XPUUQOCRSA-N Ala-Val-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O VHAQSYHSDKERBS-XPUUQOCRSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- MUXONAMCEUBVGA-DCAQKATOSA-N Arg-Arg-Gln Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(O)=O MUXONAMCEUBVGA-DCAQKATOSA-N 0.000 description 1
- UISQLSIBJKEJSS-GUBZILKMSA-N Arg-Arg-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(O)=O UISQLSIBJKEJSS-GUBZILKMSA-N 0.000 description 1
- DPXDVGDLWJYZBH-GUBZILKMSA-N Arg-Asn-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O DPXDVGDLWJYZBH-GUBZILKMSA-N 0.000 description 1
- YFBGNGASPGRWEM-DCAQKATOSA-N Arg-Asp-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N YFBGNGASPGRWEM-DCAQKATOSA-N 0.000 description 1
- PNQWAUXQDBIJDY-GUBZILKMSA-N Arg-Glu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNQWAUXQDBIJDY-GUBZILKMSA-N 0.000 description 1
- RFXXUWGNVRJTNQ-QXEWZRGKSA-N Arg-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N RFXXUWGNVRJTNQ-QXEWZRGKSA-N 0.000 description 1
- YKBHOXLMMPZPHQ-GMOBBJLQSA-N Arg-Ile-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O YKBHOXLMMPZPHQ-GMOBBJLQSA-N 0.000 description 1
- GMFAGHNRXPSSJS-SRVKXCTJSA-N Arg-Leu-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GMFAGHNRXPSSJS-SRVKXCTJSA-N 0.000 description 1
- WMEVEPXNCMKNGH-IHRRRGAJSA-N Arg-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N WMEVEPXNCMKNGH-IHRRRGAJSA-N 0.000 description 1
- HIMXTOIXVXWHTB-DCAQKATOSA-N Arg-Met-Gln Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N HIMXTOIXVXWHTB-DCAQKATOSA-N 0.000 description 1
- FBXMCPLCVYUWBO-BPUTZDHNSA-N Arg-Ser-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N FBXMCPLCVYUWBO-BPUTZDHNSA-N 0.000 description 1
- INOIAEUXVVNJKA-XGEHTFHBSA-N Arg-Thr-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O INOIAEUXVVNJKA-XGEHTFHBSA-N 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- IARGXWMWRFOQPG-GCJQMDKQSA-N Asn-Ala-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IARGXWMWRFOQPG-GCJQMDKQSA-N 0.000 description 1
- PBSQFBAJKPLRJY-BYULHYEWSA-N Asn-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N PBSQFBAJKPLRJY-BYULHYEWSA-N 0.000 description 1
- SEKBHZJLARBNPB-GHCJXIJMSA-N Asn-Ile-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O SEKBHZJLARBNPB-GHCJXIJMSA-N 0.000 description 1
- BEHQTVDBCLSCBY-CFMVVWHZSA-N Asn-Tyr-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BEHQTVDBCLSCBY-CFMVVWHZSA-N 0.000 description 1
- RGKKALNPOYURGE-ZKWXMUAHSA-N Asp-Ala-Val Chemical compound N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O RGKKALNPOYURGE-ZKWXMUAHSA-N 0.000 description 1
- ZSVJVIOVABDTTL-YUMQZZPRSA-N Asp-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)O)N ZSVJVIOVABDTTL-YUMQZZPRSA-N 0.000 description 1
- KYQNAIMCTRZLNP-QSFUFRPTSA-N Asp-Ile-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O KYQNAIMCTRZLNP-QSFUFRPTSA-N 0.000 description 1
- UMHUHHJMEXNSIV-CIUDSAMLSA-N Asp-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UMHUHHJMEXNSIV-CIUDSAMLSA-N 0.000 description 1
- WMLFFCRUSPNENW-ZLUOBGJFSA-N Asp-Ser-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O WMLFFCRUSPNENW-ZLUOBGJFSA-N 0.000 description 1
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 1
- MWZSCEAYQCMROW-GUBZILKMSA-N Cys-Gln-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CS)N MWZSCEAYQCMROW-GUBZILKMSA-N 0.000 description 1
- UXUSHQYYQCZWET-WDSKDSINSA-N Cys-Glu-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O UXUSHQYYQCZWET-WDSKDSINSA-N 0.000 description 1
- HQZGVYJBRSISDT-BQBZGAKWSA-N Cys-Gly-Arg Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQZGVYJBRSISDT-BQBZGAKWSA-N 0.000 description 1
- CIVXDCMSSFGWAL-YUMQZZPRSA-N Cys-Lys-Gly Chemical compound C(CCN)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CS)N CIVXDCMSSFGWAL-YUMQZZPRSA-N 0.000 description 1
- HJXSYJVCMUOUNY-SRVKXCTJSA-N Cys-Ser-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N HJXSYJVCMUOUNY-SRVKXCTJSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- SOBBAYVQSNXYPQ-ACZMJKKPSA-N Gln-Asn-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O SOBBAYVQSNXYPQ-ACZMJKKPSA-N 0.000 description 1
- RRYLMJWPWBJFPZ-ACZMJKKPSA-N Gln-Asn-Asp Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N RRYLMJWPWBJFPZ-ACZMJKKPSA-N 0.000 description 1
- RBWKVOSARCFSQQ-FXQIFTODSA-N Gln-Gln-Ser Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O RBWKVOSARCFSQQ-FXQIFTODSA-N 0.000 description 1
- SNLOOPZHAQDMJG-CIUDSAMLSA-N Gln-Glu-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SNLOOPZHAQDMJG-CIUDSAMLSA-N 0.000 description 1
- ZNZPKVQURDQFFS-FXQIFTODSA-N Gln-Glu-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZNZPKVQURDQFFS-FXQIFTODSA-N 0.000 description 1
- HHQCBFGKQDMWSP-GUBZILKMSA-N Gln-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HHQCBFGKQDMWSP-GUBZILKMSA-N 0.000 description 1
- JNENSVNAUWONEZ-GUBZILKMSA-N Gln-Lys-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O JNENSVNAUWONEZ-GUBZILKMSA-N 0.000 description 1
- KSKFIECUYMYWNS-AVGNSLFASA-N Gln-Lys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N KSKFIECUYMYWNS-AVGNSLFASA-N 0.000 description 1
- OSCLNNWLKKIQJM-WDSKDSINSA-N Gln-Ser-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O OSCLNNWLKKIQJM-WDSKDSINSA-N 0.000 description 1
- RONJIBWTGKVKFY-HTUGSXCWSA-N Gln-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O RONJIBWTGKVKFY-HTUGSXCWSA-N 0.000 description 1
- JKDBRTNMYXYLHO-JYJNAYRXSA-N Gln-Tyr-Leu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 JKDBRTNMYXYLHO-JYJNAYRXSA-N 0.000 description 1
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 1
- LZMQSTPFYJLVJB-GUBZILKMSA-N Glu-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N LZMQSTPFYJLVJB-GUBZILKMSA-N 0.000 description 1
- WNRZUESNGGDCJX-JYJNAYRXSA-N Glu-Leu-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O WNRZUESNGGDCJX-JYJNAYRXSA-N 0.000 description 1
- QJVZSVUYZFYLFQ-CIUDSAMLSA-N Glu-Pro-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O QJVZSVUYZFYLFQ-CIUDSAMLSA-N 0.000 description 1
- SYWCGQOIIARSIX-SRVKXCTJSA-N Glu-Pro-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O SYWCGQOIIARSIX-SRVKXCTJSA-N 0.000 description 1
- MXJYXYDREQWUMS-XKBZYTNZSA-N Glu-Thr-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O MXJYXYDREQWUMS-XKBZYTNZSA-N 0.000 description 1
- NTNUEBVGKMVANB-NHCYSSNCSA-N Glu-Val-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(O)=O NTNUEBVGKMVANB-NHCYSSNCSA-N 0.000 description 1
- SOYWRINXUSUWEQ-DLOVCJGASA-N Glu-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O SOYWRINXUSUWEQ-DLOVCJGASA-N 0.000 description 1
- MHHUEAIBJZWDBH-YUMQZZPRSA-N Gly-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CN MHHUEAIBJZWDBH-YUMQZZPRSA-N 0.000 description 1
- MOJKRXIRAZPZLW-WDSKDSINSA-N Gly-Glu-Ala Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O MOJKRXIRAZPZLW-WDSKDSINSA-N 0.000 description 1
- NTBOEZICHOSJEE-YUMQZZPRSA-N Gly-Lys-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O NTBOEZICHOSJEE-YUMQZZPRSA-N 0.000 description 1
- MXIULRKNFSCJHT-STQMWFEESA-N Gly-Phe-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 MXIULRKNFSCJHT-STQMWFEESA-N 0.000 description 1
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 1
- YPLYIXGKCRQZGW-SRVKXCTJSA-N His-Arg-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O YPLYIXGKCRQZGW-SRVKXCTJSA-N 0.000 description 1
- DQZCEKQPSOBNMJ-NKIYYHGXSA-N His-Thr-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O DQZCEKQPSOBNMJ-NKIYYHGXSA-N 0.000 description 1
- PZUZIHRPOVVHOT-KBPBESRZSA-N His-Tyr-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(O)=O)C1=CN=CN1 PZUZIHRPOVVHOT-KBPBESRZSA-N 0.000 description 1
- FFYYUUWROYYKFY-IHRRRGAJSA-N His-Val-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O FFYYUUWROYYKFY-IHRRRGAJSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- CTHAJJYOHOBUDY-GHCJXIJMSA-N Ile-Cys-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)O)N CTHAJJYOHOBUDY-GHCJXIJMSA-N 0.000 description 1
- KUHFPGIVBOCRMV-MNXVOIDGSA-N Ile-Gln-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)O)N KUHFPGIVBOCRMV-MNXVOIDGSA-N 0.000 description 1
- OVPYIUNCVSOVNF-KQXIARHKSA-N Ile-Gln-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N OVPYIUNCVSOVNF-KQXIARHKSA-N 0.000 description 1
- OVPYIUNCVSOVNF-ZPFDUUQYSA-N Ile-Gln-Pro Natural products CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O OVPYIUNCVSOVNF-ZPFDUUQYSA-N 0.000 description 1
- BEWFWZRGBDVXRP-PEFMBERDSA-N Ile-Glu-Asn Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O BEWFWZRGBDVXRP-PEFMBERDSA-N 0.000 description 1
- UBHUJPVCJHPSEU-GRLWGSQLSA-N Ile-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N UBHUJPVCJHPSEU-GRLWGSQLSA-N 0.000 description 1
- DFJJAVZIHDFOGQ-MNXVOIDGSA-N Ile-Glu-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N DFJJAVZIHDFOGQ-MNXVOIDGSA-N 0.000 description 1
- VISRCHQHQCLODA-NAKRPEOUSA-N Ile-Pro-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)O)N VISRCHQHQCLODA-NAKRPEOUSA-N 0.000 description 1
- COWHUQXTSYTKQC-RWRJDSDZSA-N Ile-Thr-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N COWHUQXTSYTKQC-RWRJDSDZSA-N 0.000 description 1
- KWHFUMYCSPJCFQ-NGTWOADLSA-N Ile-Thr-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N KWHFUMYCSPJCFQ-NGTWOADLSA-N 0.000 description 1
- UYODHPPSCXBNCS-XUXIUFHCSA-N Ile-Val-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(C)C UYODHPPSCXBNCS-XUXIUFHCSA-N 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- MJOZZTKJZQFKDK-GUBZILKMSA-N Leu-Ala-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(N)=O MJOZZTKJZQFKDK-GUBZILKMSA-N 0.000 description 1
- KTFHTMHHKXUYPW-ZPFDUUQYSA-N Leu-Asp-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KTFHTMHHKXUYPW-ZPFDUUQYSA-N 0.000 description 1
- PNUCWVAGVNLUMW-CIUDSAMLSA-N Leu-Cys-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O PNUCWVAGVNLUMW-CIUDSAMLSA-N 0.000 description 1
- ZTLGVASZOIKNIX-DCAQKATOSA-N Leu-Gln-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZTLGVASZOIKNIX-DCAQKATOSA-N 0.000 description 1
- IWTBYNQNAPECCS-AVGNSLFASA-N Leu-Glu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IWTBYNQNAPECCS-AVGNSLFASA-N 0.000 description 1
- ZFNLIDNJUWNIJL-WDCWCFNPSA-N Leu-Glu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZFNLIDNJUWNIJL-WDCWCFNPSA-N 0.000 description 1
- QJUWBDPGGYVRHY-YUMQZZPRSA-N Leu-Gly-Cys Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N QJUWBDPGGYVRHY-YUMQZZPRSA-N 0.000 description 1
- YWYQSLOTVIRCFE-SRVKXCTJSA-N Leu-His-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(O)=O YWYQSLOTVIRCFE-SRVKXCTJSA-N 0.000 description 1
- KOSWSHVQIVTVQF-ZPFDUUQYSA-N Leu-Ile-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O KOSWSHVQIVTVQF-ZPFDUUQYSA-N 0.000 description 1
- ZRHDPZAAWLXXIR-SRVKXCTJSA-N Leu-Lys-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O ZRHDPZAAWLXXIR-SRVKXCTJSA-N 0.000 description 1
- LFSQWRSVPNKJGP-WDCWCFNPSA-N Leu-Thr-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(O)=O LFSQWRSVPNKJGP-WDCWCFNPSA-N 0.000 description 1
- BTEMNFBEAAOGBR-BZSNNMDCSA-N Leu-Tyr-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BTEMNFBEAAOGBR-BZSNNMDCSA-N 0.000 description 1
- WLCYCADOWRMSAJ-CIUDSAMLSA-N Lys-Asn-Cys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(O)=O WLCYCADOWRMSAJ-CIUDSAMLSA-N 0.000 description 1
- SSYOBDBNBQBSQE-SRVKXCTJSA-N Lys-Cys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O SSYOBDBNBQBSQE-SRVKXCTJSA-N 0.000 description 1
- XDPLZVNMYQOFQZ-BJDJZHNGSA-N Lys-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N XDPLZVNMYQOFQZ-BJDJZHNGSA-N 0.000 description 1
- ORVFEGYUJITPGI-IHRRRGAJSA-N Lys-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN ORVFEGYUJITPGI-IHRRRGAJSA-N 0.000 description 1
- PLDJDCJLRCYPJB-VOAKCMCISA-N Lys-Lys-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PLDJDCJLRCYPJB-VOAKCMCISA-N 0.000 description 1
- LKDXINHHSWFFJC-SRVKXCTJSA-N Lys-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)N LKDXINHHSWFFJC-SRVKXCTJSA-N 0.000 description 1
- NYTDJEZBAAFLLG-IHRRRGAJSA-N Lys-Val-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O NYTDJEZBAAFLLG-IHRRRGAJSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AWOMRHGUWFBDNU-ZPFDUUQYSA-N Met-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCSC)N AWOMRHGUWFBDNU-ZPFDUUQYSA-N 0.000 description 1
- HLQWFLJOJRFXHO-CIUDSAMLSA-N Met-Glu-Ser Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O HLQWFLJOJRFXHO-CIUDSAMLSA-N 0.000 description 1
- TZHFJXDKXGZHEN-IHRRRGAJSA-N Met-His-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O TZHFJXDKXGZHEN-IHRRRGAJSA-N 0.000 description 1
- XPVCDCMPKCERFT-GUBZILKMSA-N Met-Ser-Arg Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O XPVCDCMPKCERFT-GUBZILKMSA-N 0.000 description 1
- DSZFTPCSFVWMKP-DCAQKATOSA-N Met-Ser-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN DSZFTPCSFVWMKP-DCAQKATOSA-N 0.000 description 1
- 101100025404 Mus musculus Myh6 gene Proteins 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102100023170 Nuclear receptor subfamily 1 group D member 1 Human genes 0.000 description 1
- 101710157490 Nuclear receptor subfamily 1 group D member 1 Proteins 0.000 description 1
- 102100023171 Nuclear receptor subfamily 1 group D member 2 Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ULECEJGNDHWSKD-QEJZJMRPSA-N Phe-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 ULECEJGNDHWSKD-QEJZJMRPSA-N 0.000 description 1
- CSYVXYQDIVCQNU-QWRGUYRKSA-N Phe-Asp-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O CSYVXYQDIVCQNU-QWRGUYRKSA-N 0.000 description 1
- OJUMUUXGSXUZJZ-SRVKXCTJSA-N Phe-Asp-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O OJUMUUXGSXUZJZ-SRVKXCTJSA-N 0.000 description 1
- OYQBFWWQSVIHBN-FHWLQOOXSA-N Phe-Glu-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O OYQBFWWQSVIHBN-FHWLQOOXSA-N 0.000 description 1
- RFEXGCASCQGGHZ-STQMWFEESA-N Phe-Gly-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O RFEXGCASCQGGHZ-STQMWFEESA-N 0.000 description 1
- FXPZZKBHNOMLGA-HJWJTTGWSA-N Phe-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N FXPZZKBHNOMLGA-HJWJTTGWSA-N 0.000 description 1
- SCKXGHWQPPURGT-KKUMJFAQSA-N Phe-Lys-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O SCKXGHWQPPURGT-KKUMJFAQSA-N 0.000 description 1
- WKLMCMXFMQEKCX-SLFFLAALSA-N Phe-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O WKLMCMXFMQEKCX-SLFFLAALSA-N 0.000 description 1
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 description 1
- ZYNBEWGJFXTBDU-ACRUOGEOSA-N Phe-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)N ZYNBEWGJFXTBDU-ACRUOGEOSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- DZZCICYRSZASNF-FXQIFTODSA-N Pro-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 DZZCICYRSZASNF-FXQIFTODSA-N 0.000 description 1
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 1
- HPXVFFIIGOAQRV-DCAQKATOSA-N Pro-Arg-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O HPXVFFIIGOAQRV-DCAQKATOSA-N 0.000 description 1
- XUSDDSLCRPUKLP-QXEWZRGKSA-N Pro-Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1 XUSDDSLCRPUKLP-QXEWZRGKSA-N 0.000 description 1
- NMELOOXSGDRBRU-YUMQZZPRSA-N Pro-Glu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCCN1 NMELOOXSGDRBRU-YUMQZZPRSA-N 0.000 description 1
- LGSANCBHSMDFDY-GARJFASQSA-N Pro-Glu-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O LGSANCBHSMDFDY-GARJFASQSA-N 0.000 description 1
- CXGLFEOYCJFKPR-RCWTZXSCSA-N Pro-Thr-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O CXGLFEOYCJFKPR-RCWTZXSCSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108010038912 Retinoid X Receptors Proteins 0.000 description 1
- 102000034527 Retinoid X Receptors Human genes 0.000 description 1
- 108091008770 Rev-ErbAß Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000594182 Sarcophaga sigma Species 0.000 description 1
- MWMKFWJYRRGXOR-ZLUOBGJFSA-N Ser-Ala-Asn Chemical compound N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(N)=O)C)CO MWMKFWJYRRGXOR-ZLUOBGJFSA-N 0.000 description 1
- YUSRGTQIPCJNHQ-CIUDSAMLSA-N Ser-Arg-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O YUSRGTQIPCJNHQ-CIUDSAMLSA-N 0.000 description 1
- DSGYZICNAMEJOC-AVGNSLFASA-N Ser-Glu-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O DSGYZICNAMEJOC-AVGNSLFASA-N 0.000 description 1
- IOVHBRCQOGWAQH-ZKWXMUAHSA-N Ser-Gly-Ile Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IOVHBRCQOGWAQH-ZKWXMUAHSA-N 0.000 description 1
- GZSZPKSBVAOGIE-CIUDSAMLSA-N Ser-Lys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O GZSZPKSBVAOGIE-CIUDSAMLSA-N 0.000 description 1
- UGGWCAFQPKANMW-FXQIFTODSA-N Ser-Met-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O UGGWCAFQPKANMW-FXQIFTODSA-N 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- PJIQEIFXZPCWOJ-FXQIFTODSA-N Ser-Pro-Asp Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O PJIQEIFXZPCWOJ-FXQIFTODSA-N 0.000 description 1
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 1
- SNXUIBACCONSOH-BWBBJGPYSA-N Ser-Thr-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(O)=O SNXUIBACCONSOH-BWBBJGPYSA-N 0.000 description 1
- VVKVHAOOUGNDPJ-SRVKXCTJSA-N Ser-Tyr-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VVKVHAOOUGNDPJ-SRVKXCTJSA-N 0.000 description 1
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- TZKPNGDGUVREEB-FOHZUACHSA-N Thr-Asn-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O TZKPNGDGUVREEB-FOHZUACHSA-N 0.000 description 1
- DEGCBBCMYWNJNA-RHYQMDGZSA-N Thr-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O DEGCBBCMYWNJNA-RHYQMDGZSA-N 0.000 description 1
- GVMXJJAJLIEASL-ZJDVBMNYSA-N Thr-Pro-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVMXJJAJLIEASL-ZJDVBMNYSA-N 0.000 description 1
- DOBIBIXIHJKVJF-XKBZYTNZSA-N Thr-Ser-Gln Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O DOBIBIXIHJKVJF-XKBZYTNZSA-N 0.000 description 1
- BPGDJSUFQKWUBK-KJEVXHAQSA-N Thr-Val-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BPGDJSUFQKWUBK-KJEVXHAQSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- IELISNUVHBKYBX-XDTLVQLUSA-N Tyr-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 IELISNUVHBKYBX-XDTLVQLUSA-N 0.000 description 1
- LGEYOIQBBIPHQN-UWJYBYFXSA-N Tyr-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 LGEYOIQBBIPHQN-UWJYBYFXSA-N 0.000 description 1
- MTEQZJFSEMXXRK-CFMVVWHZSA-N Tyr-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N MTEQZJFSEMXXRK-CFMVVWHZSA-N 0.000 description 1
- CRHFOYCJGVJPLE-AVGNSLFASA-N Tyr-Gln-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O CRHFOYCJGVJPLE-AVGNSLFASA-N 0.000 description 1
- KWKJGBHDYJOVCR-SRVKXCTJSA-N Tyr-Ser-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O KWKJGBHDYJOVCR-SRVKXCTJSA-N 0.000 description 1
- AOIZTZRWMSPPAY-KAOXEZKKSA-N Tyr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)O AOIZTZRWMSPPAY-KAOXEZKKSA-N 0.000 description 1
- DJIJBQYBDKGDIS-JYJNAYRXSA-N Tyr-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(C)C)C(O)=O DJIJBQYBDKGDIS-JYJNAYRXSA-N 0.000 description 1
- APQIVBCUIUDSMB-OSUNSFLBSA-N Val-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N APQIVBCUIUDSMB-OSUNSFLBSA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000006690 co-activation Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 108010056582 methionylglutamic acid Proteins 0.000 description 1
- 108010034507 methionyltryptophan Proteins 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000002644 neurohormonal effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 102000004164 orphan nuclear receptors Human genes 0.000 description 1
- 108090000629 orphan nuclear receptors Proteins 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 108010074082 phenylalanyl-alanyl-lysine Proteins 0.000 description 1
- 108010012581 phenylalanylglutamate Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010093296 prolyl-prolyl-alanine Proteins 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010079317 prolyl-tyrosine Proteins 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 108010015796 prolylisoleucine Proteins 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1783—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- High Energy & Nuclear Physics (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention provides a kind of nuclear receptor ROR α to prepare the application in heart failure resistance drug, the nuclear receptor ROR α is 1 hypotype of nuclear receptor ROR α, the gene order of the nuclear receptor ROR α 1 is as shown in SEQ ID NO.1, and the amino acid sequence of the nuclear receptor ROR α 1 is as shown in SEQ ID NO.2.It is found through experiments that, nuclear receptor ROR α provided by the invention is expressed in plump and failure cardiac muscular tissue and lowered, and ROR α missing can aggravate myocardial hypertrophy and heart failure.Cardiac-specific ROR α is overexpressed the Myocardial Interstitial Fibrosis that can mitigate TAC induction, improves myocardial hypertrophy and and heart failure.Nuclear receptor ROR α of the invention has the function of resisting cardiac hypertrophy and heart failure.
Description
Technical field
The invention belongs to biomedicine field more particularly to cardiovascular drugs, and specifically a kind of nuclear receptor ROR α exists
Prepare the application in heart failure resistance drug.
Background technique
Heart failure is the serious and terminal stage of various heart diseases, and disease incidence is high, is current most important angiocarpy
One of disease.The main reason for heart failure is industrialized country's crowd's death rate only just causes about in the whole world for 1 year 2012
108000000000 dollars of economic loss.Heart failure refer to tranquillization or stress under, since any cardiac structure or dysfunction are led
The ventricular filling of cause penetrates the impaired a complex set of clinical syndrome of blood ability, and main clinical manifestation is expiratory dyspnea and weary
Power (activity tolerance is limited) and fluid retention (pulmonary venous pleonaemia and periphery oedema).
One of main pathogenesis of heart failure is cardiomyopathy rational reconstruction, and myocardial hypertrophy is usually in pressure/volume
Under the stimulation of excess load and Neurohormonal factor, cardiac muscle acts on a kind of adaptability myocardial remodelling of wall stress.Although rising
First myocardial remodelling can play the role of compensatory, but the myocardial hypertrophy of this maladjustment has been considered to be a kind of promotion at present
The strong effective predictive factor of the important independent hazard factor and the death rate of chronic heart failure disease progression.Myocardium fertilizer
Thick pathological change includes that cardiac myocyte hypertrophy, myocardial interstitial cells proliferation and the reconstruct of heart cell epimatrix etc. are various
Change.Show as that the synthesis of cardiac muscle cell's albumen increases, volume increases, diameter is broadening or length increases, muscle segment number in cellular level
Amount increases and with proliferation of fibrous tissue.In the progress of myocardial hypertrophy, main molecular mechanism includes multiple protein phosphatase
The activation of cascade signal access, the starting of embryonic gene expression system again, the cardiac damage of calcium-mediated and active oxygen
Accumulation.The slow progress for aggravating that myocardial remodelling can be promoted of oxidative stress, and the excessive accumulation of active oxygen is considered as pathologic
The important triggering factors of myocardial hypertrophy and heart failure.Therefore, it for myocardial hypertrophy and heart failure, finds new can effectively inhibit
The recruit of myocardial hypertrophy and the pathologic, physiologic of failure progress may have important control especially with respect to the accumulation of active oxygen
Treat value.
Nuclear receptor superfamily is the transcription factor of a kind of ligand-dependent, the development of mammal, metabolism, cell Proliferation,
It plays a significant role in differentiation and numerous pathophysiological processes such as apoptosis and the important molecule of numerous U.S. FDAs certification drug
Target spot.Retinoic acid related orphan nuclear receptor (Retinoid-related orphan receptors, RORs) is because it is in gene sequence
It is similar to retinoic acid receptors and retinoid X receptor and gain the name on column.RORs is by ROR α, 3 hypotype compositions of ROR β and ROR γ.
Wherein ROR α, also referred to as NRlF1 (Nuclear receptor subfamily 1, group F, member 1), are nuclear receptors
Embryonic development, an important member of circadian activity and Metabolism regulation are participated in family.ROR α wide expression in heart,
Many internal organs such as brain, skin, thymus gland, lung and kidney.Similar to other nuclear receptors, ROR α includes four structural domains, from amino end
Hold carboxyl terminal to be followed successively by amino-terminal end structural domain, DNA binding domain (DNA binding domain, DBD), hinge area and
Ligand binding domain (Ligand binding domain, LBD).ROR α is reacted by DBD with enhancer region AGGTCA half site
Element, that is, ROR alpha reaction element (ROR α response element, RORE) leads in conjunction with come the transcriptional activity that regulates and controls target gene
Sequence of the upstream rich in A/T is crossed to regulate and control the specificity of its DNA combination.There are two zinc fingers by DBD, are respectively used to identification groove
Core motif and RORE 5 '-end at position are rich in the sequence of A/T, can effectively excite the phase interaction between ROR α and RORE
With.LBD is an important multifunction structure domain, not only can with binding partner, participate in nuclear location, moreover it is possible to provide with co-activation because
The site of son or co-suppression factor interaction, so that ROR α can generate diversified gene regulation in different histocytes
Effect.ROR α and DNA combination when, also by the Reverse transcriptase of other nuclear receptors, such as REV-ERBA α and REV-ERB β
Also can identify RORE, and by with ROR α competitive binding to RORE, thus the transcriptional activity for inhibiting ROR alpha mediated.
It can detecte the expression of nuclear receptor ROR α in vascular system, and be determined that it sends out in the pathologic, physiologic of blood vessel
Wave important role.Our seminar research discovery ROR α can be used as one and resist the endogenous of myocardial ischemia-reperfusion injury before
Property defense molecule.It in addition, there will be research shows that nuclear receptor ROR α, which is one, can regulate and control the important of a variety of antioxidant genes expression
Transcription factor.A possibility that above-mentioned discovery prompt ROR α plays latent effect in heart failure.However, ROR α is in myocardium fertilizer
The thick effect with failure is still unmanned so far to be reported.
There are 4 four ROR α 1, ROR α 2, ROR α 3 and ROR α hypotypes in people by ROR α, and wherein ROR α 1 is typically to have
Representative hypotype is made of 523 amino acid residues.Its gene is located at No. 15 chromosomes, and site information is as follows:
Homo sapiens chromosome 15q22.2,GRCh38.p7(GCF_000001405.33),NC_
000015.10(60488284…61229303,complement)。
Transcribed formation four transcripts, respectively transcriptional variants 1 (NM_134261) of the gene, 2 (NM_ of transcriptional variants
134260), transcriptional variants 3 (NM_002943), transcriptional variants 4 (NM_134262).Wherein transcriptional variants 1 (NM_134261)
The gene order such as SEQ ID of (Retinoid-related orphan receptor α, transcript variant 1)
Shown in NO.1.The albumen ammonia of representative hypotype ROR α 1 (Retinoid-related orphan receptor α isoform 1)
Base acid sequence is as shown in SEQ ID NO.2.
Summary of the invention
The purpose of the present invention is to provide a kind of nuclear receptor ROR α to prepare the application in heart failure resistance drug, described
This nuclear receptor ROR α will solve to treat and prevent heart failure in the prior art in the application prepared in heart failure resistance drug
The bad technical problem of effect of drugs.
The present invention provides a kind of nuclear receptor ROR α to prepare the application in heart failure resistance drug.
Further, the nuclear receptor ROR α is nuclear receptor ROR α 1.
Further, the gene order of the nuclear receptor ROR α 1 is as shown in SEQ ID NO.1.
Further, the amino acid sequence of the nuclear receptor ROR α 1 is as shown in SEQ ID NO.2.
The present invention provides a kind of nuclear receptor ROR α with potential treatment heart failure effect, this receptor can effectively change
Kind myocardial hypertrophy and its caused heart failure.
It is experimentally confirmed, nuclear receptor ROR α is expressed in plump and failure cardiac muscular tissue and lowered.
It is experimentally confirmed, ROR α missing aggravates myocardial hypertrophy and heart failure.
It is experimentally confirmed, Cardiac-specific, which is overexpressed ROR α, can mitigate Myocardial Interstitial Fibrosis, improve myocardial hypertrophy
And heart failure.
It is experimentally confirmed, discovery nuclear receptor ROR α, which mainly passes through, to be reduced oxidative stress performance resisting cardiac hypertrophy and decline
The effect exhausted, and the effect mainly by manganese superoxide dismutase (Manganese superoxide dismutase,
MnSOD) anti-oxidative stress mediated plays.
The present invention is compared with prior art, and technological progress is positive and apparent.A kind of inhibition heart provided by the invention
The nuclear receptor of force failure: retinoic acid correlation orphan nuclear receptor-α (Retinoid-related orphan receptor- α, ROR α)
Have the function of resisting cardiac hypertrophy and heart failure.
Detailed description of the invention
Fig. 1 is expression changing rule of the ROR α in plump and failure cardiac muscular tissue.
Fig. 2 is influence of the ROR α missing to myocardial hypertrophy and heart failure.
Fig. 3 is influence of the Cardiac-specific ROR α overexpression to myocardial hypertrophy and heart failure.
Fig. 4 is that ROR α mitigates myocardium oxidative stress.
Fig. 5 is the expression that nuclear receptor ROR α can raise manganese superoxide dismutase (MnSOD).
Specific embodiment
The following is specific embodiments of the present invention, and the embodiment described is rather than to limit this hair for describing the present invention
It is bright.
Reagent used in the examples and experimental method are as follows:
Molecular biochemistry reagent: protease and inhibitors of phosphatases, beta -mercaptoethanol, lauryl sodium sulfate, Tris
Alkali etc. is purchased from the U.S. Sigma, and BCA quantification kit, ROR Alpha antibodies are purchased from the U.S. Thermo Scientific, and 30% methene is double
It is the U.S. Bio-Rad that acrylamide, which is purchased from, and Triethanolamine buffer (TBS), Tween-20, phosphate buffer (PBS) etc. are purchased from
Raw work biology China, horseradish peroxidase chemical luminescence for liquid are purchased from the U.S. Millipore, and isoflurane is purchased from composite tablet
State, ribonucleic acid Reverse Transcriptase kit, picodna amplification kit are purchased from Takara Japan, MnSOD antibody, GAPDH antibody
Purchased from the U.S. Cell Signaling Technology, horseradish peroxidase antibody is purchased from the U.S. Jackson.
The foundation of 1 mouse cardiac muscle pathologic hypertrophy model of embodiment
10-12 week old mouse is put into anesthesia tank, continues the isoflurane that inhaled concentration is 2% through Anesthesia machine and is anaesthetized
(Ventilation Rate 2L/min).Trachea cannula connects ventilator and maintains breathing.Sterile surgery region takes front median incision to open chest to
2 ribs separate thymus gland, the exposure arch of aorta.Acupuncture treatment pad is padded with 27G to prick, and by aorta and pads acupuncture treatment one with 7-0 surgical nylon suture
And ligature, chest, seam skin are successively closed in extraction pad acupuncture treatment after ligaturing really.After mouse autonomous respiration recovery, trachea cannula is extracted,
Mouse is placed on heated at constant temperature blanket until it revives from anesthesia.Sham-operation group is ligatured without the arch of aorta, remaining process
It is completely the same with operation group.
Bend different time points (1 week, 2 weeks, 4 weeks, 8 weeks) afterwards Constriction (TAC) in C57BL/6J mouse row aorta, uses
The method of immunoblotting and real-time fluorescence quantitative PCR detects ROR α in transcription and translation level, finds its expression with TAC
Post surgery duration gradually lowers (Fig. 1).
Wherein Figure 1A is the representative immunoblotting picture of ROR α, and the result of sxemiquantitative is carried out to immunoblotting;Figure 1B
For the real-time fluorescence quantitative PCR result histogram of ROR α.
Embodiment 2
The evaluation of toy cardiac ultrasonic:
Mouse with 2% isoflurane is continued into inhalation anesthesia and dorsal position is fixed on the ultrasonic examination platform of included heating function
On, its pareordia mouse hair first is sloughed with depilatory cream, uses 770 diasonograph of VeVo and 30MHz of VisualSonics company
High frequency probe acquires parasternal long axis section, apical four-chamber section, record electrocardiogram, measurement heart rate on the wall of the chest.In parasternal
Mitral level obtains two-dimensional ultrasound tangent plane picture under left room short axis view bicuspid valve, measure left room shrink last internal diameter (LVIDs),
Left ventricular end diastolic diameter (LVIDd), Left Ventricular Ejection Fraction (LVEF) and shortening score (LVFS).The instrument ginseng that each group mouse checks
Number setting keeps identical, and carries out Image Acquisition and calculating by same people, and each measurement index chooses 4-5 different week aroused in interest
The average value of phase.
The ROR α of C57BL/6J background lacks (ROR αsg/sg) mouse be purchased from the laboratory U.S. Jackson.10-12 week old SPF
Grade ROR αsg/sgMouse and its wild type control mice (WT) assign to TAC group and sham-operation (Sham) group at random.After TAC 8 weeks into
A series of coherent detections of row, find ROR αsg/sgMouse cardiac myocytes cross section significantly increases, and cardiac weight dramatically increases, petty action
Object Cardiac ultrasound prompts ROR α missing heart function to deteriorate aggravation (Fig. 2).
Wherein Fig. 2A is that the representative HE of each experimental group dyes picture;Fig. 2 B is quantifying for each group cardiomyocytes cross-sectional area
As a result;Fig. 2 C is the statistical result of cardiac weight and weight ratio;Fig. 2 D is the left room shortening point of each experimental group cardiac ultrasonic measurement
Number.
Embodiment 3
Mouse ROR α full length cDNA sequence is incorporated into mouse α-myosin heavy chain promoter downstream, to construct C57BL/
The Cardiac-specific ROR α of 6J background is overexpressed mouse (TG).SPF grades of ROR α-TG mouse of 10-12 week old and its control mice
(NTG) TAC group and Sham group are assigned at random.Carry out a series of coherent detections within 8 weeks after TAC, discovery ROR α-TG mouse cardiac muscle is thin
Born of the same parents cross section reduces, and cardiac weight significantly mitigates, and heart function is improved (Fig. 3).
Wherein Fig. 3 A is that the representative HE of each group dyes picture;Fig. 3 B is the quantitative knot of each group cardiomyocytes cross-sectional area
Fruit;Fig. 3 C is the statistical result of cardiac weight and weight ratio;Fig. 3 D is the left room contracting of each experimental group toy cardiac ultrasonic measurement
Short score.
Embodiment 4
DHE dyeing: superoxide level in fresh cardiac muscular tissue's frozen section is detected using dihydro second ingot (DHE) dyeing.
With PBS dilution DHE concentrate (1mmol/L) to 10 μm of ol/L, it is kept in dark place spare.The Fresh Frozen cut is taken to be sliced, investment
In PBS solution, washing 3 times are stood, then each 3min carefully wipes remaining moisture.Add about 40 μ l on each section sample
DHE working solution, negative control group add 40 μ l of PBS.It is protected from light 37 DEG C of incubation 30min of constant temperature.DHE working solution is sucked, investment PBS is molten
In liquid, washing 3 times, each 3min are stood.Then covered pays attention to that bubble is avoided to generate.It is aobvious in laser scanning co-focusing
It takes pictures and stores under micro mirror.As a result prompt ROR α missing obviously increases hypertrophic cardiomyopathy tissue oxidizing stress level, and ROR α mistake
Expression then can reduce oxidative stress (Fig. 4).
ELISA detect nitrotyrosine content: nitrotyrosine (NT) be protein oxidation stress product, indirectly reflect
Oxidative stress.It is operated according to Abnova company nitrotyrosine ELISA kit specification, takes out in liquid nitrogen and save
Cardiac muscular tissue, the protein lysate for preparing in right amount is added, is fully ground into homogenate with electric grinder.And it is measured with BCA method
Each protein sample concentration.10 × sample diluent is diluted to 1 × working solution with ddH2O, cleaning solution is diluted by 1:40, then
It is spare to be placed in room temperature.Compound concentration gradient standard items.It is loaded and reads the light absorption value that wavelength is 450nm in microplate reader.Foundation
The concentration and absorption values of standard items make standard curve.The concentration of sample to be tested is calculated according to standard curve.As a result it shows
Show that ROR α missing obviously increases hypertrophic cardiomyopathy oxidative stress, and ROR α overexpression then can reduce oxidative stress (Fig. 4).
Wherein Fig. 4 A is the DHE relative intensity of fluorescence quantitative result of ROR α missing and its control mice heart;Fig. 4 B is ROR
The nitrotyrosine ELISA quantitative result of α missing and its control mice heart;Fig. 4 C is ROR α overexpression and its control mice heart
Dirty DHE relative intensity of fluorescence quantitative result;Fig. 4 D is the nitrotyrosine ELISA of ROR α overexpression and its control mice heart
Quantitative result.
Embodiment 5
After the completion of sample protein preparation, polyacrylamide concentration glue is added in 50 micrograms of protein samples with micro sample adding appliance and is added
In sample hole.Using SDS-PAGE vertical electrophoresis.Wet process transferring film is then used, after transferring film, takes out nitrocellulose filter with de-
Rouge milk room temperature is closed one hour.4 degree are incubated overnight primary antibody MnSOD and GAPDH.It is incubated within second day corresponding horseradish peroxide respectively
After the secondary antibody of compound enzyme label, it is imaged on Chemiluminescence Apparatus.Gained picture is exported as into tiff format, and to target item
Reinhoit Zahl with MnSOD and internal reference GAPDH does quantitative analysis.Experimental result prompt ROR α missing can reduce hypertrophic cardiomyopathy group
The expression of MnSOD is knitted, and ROR α is overexpressed the protein expression level (Fig. 5) that can then restore MnSOD.
Wherein Fig. 5 A is the MnSOD representativeness western blot figure and MnSOD band of ROR α missing and its control mice heart
Semi-quantitative results;Fig. 5 B is the MnSOD representativeness immunoblot results figure and mesh of ROR α overexpression and its control mice heart
Band semi-quantitative results histogram.
Sequence table
<110>Renji Hospital Attached to Medical College of Shanghai Jiaotong Univ.
<120>nuclear receptor ROR α is preparing the application in heart failure resistance drug
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 10828
<212> DNA
<213>nuclear receptor ROR alpha transcriptional variant 1 (Retinoid-related orphan receptor α)
<400> 1
ggtaccatag agttgctctg aaaacagaag atagagggag tctcggagct cgccatctcc 60
agcgatctct acattgggaa aaaacatgga gtcagctccg gcagcccccg accccgccgc 120
cagcgagcca ggcagcagcg gcgcggacgc ggccgccggc tccagggaga ccccgctgaa 180
ccaggaatcc gcccgcaaga gcgagccgcc tgccccggtg cgcagacaga gctattccag 240
caccagcaga ggtatctcag taacgaagaa gacacataca tctcaaattg aaattattcc 300
atgcaagatc tgtggagaca aatcatcagg aatccattat ggtgtcatta catgtgaagg 360
ctgcaagggc tttttcagga gaagtcagca aagcaatgcc acctactcct gtcctcgtca 420
gaagaactgt ttgattgatc gaaccagtag aaaccgctgc caacactgtc gattacagaa 480
atgccttgcc gtagggatgt ctcgagatgc tgtaaaattt ggccgaatgt caaaaaagca 540
gagagacagc ttgtatgcag aagtacagaa acaccggatg cagcagcagc agcgcgacca 600
ccagcagcag cctggagagg ctgagccgct gacgcccacc tacaacatct cggccaacgg 660
gctgacggaa cttcacgacg acctcagtaa ctacattgac gggcacaccc ctgaggggag 720
taaggcagac tccgccgtca gcagcttcta cctggacata cagccttccc cagaccagtc 780
aggtcttgat atcaatggaa tcaaaccaga accaatatgt gactacacac cagcatcagg 840
cttctttccc tactgttcgt tcaccaacgg cgagacttcc ccaactgtgt ccatggcaga 900
attagaacac cttgcacaga atatatctaa atcgcatctg gaaacctgcc aatacttgag 960
agaagagctc cagcagataa cgtggcagac ctttttacag gaagaaattg agaactatca 1020
aaacaagcag cgggaggtga tgtggcaatt gtgtgccatc aaaattacag aagctataca 1080
gtatgtggtg gagtttgcca aacgcattga tggatttatg gaactgtgtc aaaatgatca 1140
aattgtgctt ctaaaagcag gttctctaga ggtggtgttt atcagaatgt gccgtgcctt 1200
tgactctcag aacaacaccg tgtactttga tgggaagtat gccagccccg acgtcttcaa 1260
atccttaggt tgtgaagact ttattagctt tgtgtttgaa tttggaaaga gtttatgttc 1320
tatgcacctg actgaagatg aaattgcatt attttctgca tttgtactga tgtcagcaga 1380
tcgctcatgg ctgcaagaaa aggtaaaaat tgaaaaactg caacagaaaa ttcagctagc 1440
tcttcaacac gtcctacaga agaatcaccg agaagatgga atactaacaa agttaatatg 1500
caaggtgtct acattaagag ccttatgtgg acgacataca gaaaagctaa tggcatttaa 1560
agcaatatac ccagacattg tgcgacttca ttttcctcca ttatacaagg agttgttcac 1620
ttcagaattt gagccagcaa tgcaaattga tgggtaaatg ttatcaccta agcacttcta 1680
gaatgtctga agtacaaaca tgaaaaacaa acaaaaaaat taaccgagac actttatatg 1740
gccctgcaca gacctggagc gccacacact gcacatcttt tggtgatcgg ggtcaggcaa 1800
aggaggggaa acaatgaaaa caaataaaag ttgaacttgt ttttctcatg catatgattt 1860
ccattatgcc tacagatatg gacccttttt ctgtcttgac ttcttgatca ttgacctctg 1920
tttacaacag gaggagggta ctaaagtcgg aggatttcct tttcttgtag ctcactgccc 1980
acagactttc tacagagtca ccaatctgtc agtaacaaca gagagtccag caataatcgg 2040
tgactggtgt gcatagcgga ggttgcggca ttactttgca caactagctc tttgtttcat 2100
gaaggaagtt tttatttttt caccgattat tgccagtccg caggatggca tgaaaagggt 2160
ccatagcagt agcaacaata gcattataat atattacagg gtaaatgggc atgaagacta 2220
tatatagcta aaagagatat tgtttatata ttgttttaag taatataaaa tgtagttact 2280
ggtgtagctt ttcctgttga attgataagg cactttcatt ttgcaccttt ttctttaaat 2340
taaatgctag cgtgttcact gtcgtgtcgc atgtgcacca gaaacacaag tttaactgag 2400
aaggcttgga aggtacgttg ggaggtattt atgctgctgt ttacaaaatt atttttaaga 2460
gactggctgg tcatatctag aaatcaccac gttggatttt ttttttaaca tgtgaatttg 2520
gaattagaaa cggaactctc cctaaattat actttgcttt ttggtaagtt taatgataga 2580
tgtgtttatg cttcatacaa agttgaatga ttgattggcg tggtggacat ataccatcat 2640
gctcattttt tttttttaaa gctttttaaa atgccacctc atggaggcga gggggaggag 2700
aagctcattt tacacaattc agtagttaaa tatggactcg gtctcaactt ggaattctta 2760
tgctttgaga acaaatcaac aaccagaata tttattggaa tctagctttt attataagaa 2820
ggacccaaag attatatcct gagcaaatgc acactcccca tgtgaggaca tgaagtattt 2880
actttgtgaa tgtttatgtt cttggtataa tctaggaacc ctatgagttt atctcagagt 2940
gaactaattc tagatttgtt gtcaatagat gctataattc aagaatgttg ctctccatat 3000
ttgaaaaacg atggatagga gggtgaggga agcatacaat gttgaaccag tttctcttat 3060
ttaaatatta aatactttaa gcctttaaag tgaagttgat gctagctgca aacatttact 3120
cttgtattta tcttcactag gaaactgtgg actgtaattt attttattaa atatttagaa 3180
gattatttgg cttgtgtgtt caggtgagaa atactgagtt gtttttgttt aatttcatgg 3240
tttttttttt tttaatgatc cctagtgggg gaaggggaaa ggaatagtct gataaacaga 3300
tgtgcatatt ttaaaaacaa gtgacctttt gggaatgtag gcatttagac gatgatttta 3360
gtcgcactag gggtgggatt caaactactg gtcaaagacc attttgtaca gaaaagggaa 3420
catctccgat gggtgttaag gtaggagttt ccatgcagcc ctttatgtct gagaaatagt 3480
ctcctctgcc attggggtcc ctgcggaatc ttctacagga attgcagctc ttcacgtcat 3540
gctaggttac cagcatgggc ttcccagagc acttcactct gtttctaact ccactgactt 3600
ttctgacttg tttcttgagg gacttggaaa aggggaaggt attattcaca cagatgtgtg 3660
tatgaagcct aaataacatc caactttttt tccaaaaaca tagtaagagt ttaaccataa 3720
atagaagagt aatattcctt taaatttctt acaggcatgt aaaattttat gtgtttatag 3780
agagatgcta actgtcagca tatagtattt atattggggc aagaagggtt aaatcaaatc 3840
tttaatttaa gtaagcatag ttcctttaaa gatcagtagt atttatactc tgaaaagagt 3900
accaagctta gttcagttat ttattcatcc attttttttc tattgtttct cctctggggg 3960
gaaatggtgt tttgtttttg tttgagtttt gtgttttagt tttttggttt tggttttgtt 4020
ttgttttttt gtcattcaga ttcactaaat ttggggatgg ttttattaaa gtatattaac 4080
ttctttttaa ccaaagcttt ctgaatatga ccagcctcag gtgctagcgc attaaagagc 4140
aactaaacct aattccagtg tcgatttgtg aaataataaa agctaattga atttctctaa 4200
gggtgagaga gaacataatg atgaacttaa aaagaaattc cttttcccag aagggattct 4260
gcatgtacct acaaacaatc atgctctaac cacagtaata gtcatgccat ggtgacattg 4320
cttttacggt aaaccaagat aggtaatatg atgcttcttc ccaggtgttt ctgaaagaaa 4380
agcagcggtg gagcttaaga gccaagtcca ctgattgaca taataggatg gaattgtaga 4440
cagagacatg ctccatgaaa caaggaaaca actgactact atttggatct aagttgggat 4500
ctgatgttaa acaataaatt cagtttaaaa aaaatatgga gctcagaaaa ggatgtgaaa 4560
aactttgcat tttcctttct tcattattac aaaaacacct atgtgatgac ataaaatact 4620
tgggtgatat cagaacaatt atccttaata gtttttataa ttaaagtttc ctaaacttca 4680
gtctccaata gtcttttaag gattggaacc acatcactgt cagccccgct gctacaatgc 4740
ctttgtacaa tttttttaca taaggcaaat aaggcttttg tacaaagcct gaataccttc 4800
tgttccaatg gtgtccaaat ggttattata ttgtgaaaaa cctggccttg gtcacaatgc 4860
aaacaaaagt acagatgaaa gtgctttttg gacagtttgc aaattgtgtt aaagctacgg 4920
atttttttta aagtgttcag catcttaacg tgtattaaag ctatggattt ttttttaaag 4980
tcttcagcat cctaattcac cctttctaac ttaagaaaaa catgacttaa gacactgctt 5040
ctaagtttgg ttgttcttta tagtgtggat acccagttat ctgtgagcgt atgggggtgg 5100
gctgagggtc aggtgaggaa ggagtgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg 5160
tgatttgcat gtgtatgatg tgtgtgcgtc ggaccgcttc taggctacta agtgtcaatg 5220
gaaaagaaaa tgtattcaaa atacttaaat caaaactaga agatggggaa aaaaagattt 5280
attctataca aagccttgtc tggaccactt tagagagact tctatttttt taacccttct 5340
ataaatattt gatggcactt gaaatattcc tgcaataaaa tgtgatttgt gtaaagaaaa 5400
aaagattttg taatgtgaaa caaagaaaga aagtaatgta attttctaaa aaaaaaaata 5460
caaacaaaca aactttgtat tattttcttg atggaatttg tctatctgtc tttggaaaac 5520
tttttatttc attgaatgtg ccatagtaga aatgtgtgtt tttagtttta gactaaggaa 5580
tagctagttg ttgtgttccg acattccaaa atgcaaaaca acctagtagt atctttcatg 5640
aaaaggttta agtagtatgt aagcttctct cattgttgct tttttgcaca tgttcttcat 5700
tcctctctag tgcaatatgt acatagagca cttgcgggtg taccttgatc cctcagggaa 5760
aaatacatat ttgtacagtt ttttggggtt tttttgtttt ttggtttttt ttgttttgcc 5820
ttttgttttt ggctaaggaa tgtcgatcga atcacttgtt attgttgagg ggcagccaga 5880
taataatcct aaagccactg tttccaacat tgattgttta aatcatatgt ccttccaatg 5940
ctattatttt aagataataa taaaaagtta ttttctgaca gttctttgtg ctgactggtg 6000
aaaaacaagg gtaaataagc accttataat tgacttactg tgaatgacaa tccatcttgg 6060
tatcaacgat agaagcccta tcattttgga gttggggtta agagtcagaa acaatgtgct 6120
cagggatctc ctaaaactct taaaacaggg tggccagtac tactgggaca aattgtgttt 6180
tttattatta ataataatga taataatact atccctccaa ggcacaagtg aactatatag 6240
aactgcgtgt gtgtaaactc tttactctcg tctcattttg ttgagtttag aacttgatgt 6300
gctcgtcagt cttgtgtttc aaaacactga ataacttcca aagcaaagtt atgccagtgt 6360
gttcaaaaga taaattaata atgtaccagc aaagagcatc attcaaagta tagtccttgc 6420
atattccagt taccatttct ctaataatta aaatattcat gataaatata tatatagcat 6480
catatgttaa aaactatttc aaattctaca tattaaggat gaaaatttta aaatccagta 6540
ataagaggag agacctgcct atcagtacag tgatataggt aaaagatgaa atatgttttt 6600
aaaataccag caattaacta ttgttttcat gggttctcct ctagaagcaa accaaaaatt 6660
ccttcatgga aaacaattct tacttctaca tgtgtagttt atatctgatg cattacaaga 6720
gctaatgttt aaagacaaaa caaaacctgc ctgtatgaca gcagcaactc gagccaacat 6780
ttagtgttac atgttatatt tttgaaatac cgttttgtta tcatattcca catattactt 6840
tccataaagt cagagaagtt caatgtaatt gttggctctg attcttccac cttgggatac 6900
acattcacaa gaagatttat atattttctt actatgatag aggaacataa tctgggaaaa 6960
cttcccatgt ctgtaagatg aaaaggatac ctttaccatg ttgtttttga taataaagaa 7020
tatggaaaat ggtagaaatc tctcctctct atgtgtattt gtatatgtgt gtatacacac 7080
acacgttgac atttttacat aacatgtgat tgccacttct tataaagtta tgatatagaa 7140
ccccatgaaa acaactttat attatagatc aaataatgtg cccagaaacg caattgcaac 7200
agtaaatctt gatctattgg taagagtcta tgatacaggt cttcattcta tccctaaaca 7260
taatgttagt aaagaggttc catcagattg tattatagag accttcctat tgctatttat 7320
ttttaagaga tgagaagact gactagcaat gtctccacag tgcaattggt ttcacttctg 7380
ggtctgtctg tctgtttgtg taggtgagat cagtgttgtc aggctctcag aataattttt 7440
aaaagaatcc agaagcctga cttcacacca agtagccatc ctagatgggc gggggggatc 7500
tccatgttca accaaaccct cagaacttag agcaataaat acattcagtc atttatttat 7560
aaatgaatga cagaatattc aatccaaata gaaacaacct tttgtcagtg atgcaacata 7620
acatggagtc ttatattgag aaagtgaata tgaatatttt aaatagatgc ctaggaaatc 7680
tgtgtttgct gtttacattt aatgtacttt gccacattag cagtaccaca cttcttttac 7740
tttcatcctt ctaagaacta atgaaagata gcttgctatt agctttgaca tgttgcacat 7800
gccattatgt tgttctctaa gaacaactaa attctctcca gtgttcatgt gtgattcctt 7860
tttcatcatt attactttaa tgtggatgaa tactatttct aggaacttga ttatcactga 7920
acagattgca tatgtaaatg cagataattc ttgagcaata tagtgaaaat gatttcacaa 7980
aaaaaatcca tatgtactgt atacatcttc ctgaatccaa aattctcctg ttatccacac 8040
agtttgaaat ctcatattaa acagtggtaa atttttaaac attaggacat tagctggctg 8100
cttctataaa tgtacctgta ttgtctgcct gctccttttg tggagatgtg tttttgtatt 8160
ggatgtttgg gccaatggga ggcttcaagc tacaacatat tttcccactt taaataatat 8220
ttaacatatg acaaacccca gacaaggctt ttaatatgta taaagaactg cagtgttagg 8280
tggtttattt gcaaactgtt ttcagtgttg tccattttta tggcaccttt aacaatattc 8340
ttgtttccaa agtacaaaaa aaataggtta aataatctag ccataactga atgtcaagca 8400
ataaaacaaa tgacttttgt gcatagactt aaaaaataca aattttagac atctgcatgt 8460
aaatgcaatc tcttgtttac tgctttcttc aacttgagca atcgattcct tatttactat 8520
taacttaaga acttgtaacg gcctgtaaac attttctctc ttactcttct ttcaaattta 8580
cctgtccctg cttttgagtc ataatattta atgttgttct gcacatctct atacagttaa 8640
ctttttggct ttcattctgt atagataaga aaatgttata ttataaacag cctactcagt 8700
gcaaatattt atctgtttat caaatccaca atatgctgta taataccggt tttactatat 8760
aatctatttt agacatagct gtttagaact agagtgtgct atttttgtgt ttttctgatg 8820
tgtggtgcta gacaagttac ttttgtgaac aacaaaaatt atccctttta ttcctagaca 8880
ataccacctt tgggtcttgt taatttcact gagtataact atatatttgt atatatatac 8940
atatatatat atatctacct atgcccaact ggcagctgta tcagagtgct ggatttggga 9000
catgcttttc tctttaaata cataatatca ttatataaat tattctagag tgtatttaat 9060
taggataaaa ttacttcctt agtatggata tttgacatct atagggtgaa tttgtttata 9120
aatatggcta tatggaaact tattagcatt tactttatgt ttgctacttg gctttacagc 9180
atatctccta agctgaaaaa taatttgcca ggccttcaag atcctaaaga aacttgttta 9240
atggagtaat atactttttt ttcttattaa ggaattgtat tactggcacc taacacagtt 9300
gtattcttag ctcctattat agataatggg catttacata aaatatccta gatggcttga 9360
tggcagaata aacctttccc ctcctacctg agtcatgaga aggatggaga cgtcctctgc 9420
cataacatgg gccataaagc aaattcgaca tgggatgttc tgtttcagta tgacctcaac 9480
cagttccatg aactgagtga aggaccttca ttttcaaagt tatttaataa gtagcttaat 9540
taagcctttc tacccattct cccaagatct actggcatta ttgaaaagca aagtttatca 9600
aatatctaac taaggatgta gttaacctta ttaaatattg attagaattg ttctgtaata 9660
ttactgaatt tgtaagatct ttagcaaaga tttttgagca atttataaat gtagagcaaa 9720
tgtttctgtt tactgcactt tttgtaactg aaggtgataa attctcaagc catgattatt 9780
ggcttccatg cactgcaata tttatccaca attctagaca ttttccattt ttgtggaaga 9840
gttgctgtta ccttaattat aaatgcaatt gtgtggttaa tgagagctaa tgctagtagt 9900
taacctttta aagtggattg gctacagttg agggagaaat ctcttttaat ataaatcaca 9960
tcattcctta actgcctctc ttggaaagag attgaaacct tttttttaaa gcacgattta 10020
gcatcctaag cttcctgagg gtagagattg tatctttttg cgtctgcaca atggctagca 10080
catgtcagca tttgacaatt gttaaatgat aacaagtgtg ccccaattaa aacgtttttc 10140
ctgggttgtt ttgttaaatt tacaaagtaa gccaagcctt acggttaaca ttctcctcta 10200
caaccaagta ttaaagccac atttaaaaag accacatgaa atgctgattc taattgtgtg 10260
taggtcttga ggattaagca cacaaatttc acaaacttct gtttgagtaa acaaactcag 10320
ccttctgtaa atatacatgc aagtttggaa acagtaatac tgtacctata aatatatgct 10380
gtctgttttg tgtacagtat gtaaaaactc cttttctgcc acactaaaaa tgcaagccat 10440
ttatgggaat cctaaaacta gtattgaact aaaactttgc taatgatctt tattagagga 10500
tcgtccaact tttcacttac cttgggtttt cttttcaatt cactcttaca ctagtctgct 10560
tatttccagc tgtttatttt attgagtcct gaatttaaaa aaaaaatatt ttgattcatt 10620
ttgtaaatac aagctgtaca aaaaagagag atttaatgtt gtcttttaaa tactccaatt 10680
ttcattctaa tatgaatgtt gttatattgt acttagaaac tgtaccttta atattacatt 10740
acctttatta aaagtgcatt gaacacatca attttagatg tgctttatgt actgttatcc 10800
tataataaaa cttcagcttc taatggaa 10828
<210> 2
<211> 523
<212> PRT
<213>1 hypotype of ROR α (Retinoid-related orphan receptor α isoform 1)
<400> 2
Met Glu Ser Ala Pro Ala Ala Pro Asp Pro Ala Ala Ser Glu Pro Gly
1 5 10 15
Ser Ser Gly Ala Asp Ala Ala Ala Gly Ser Arg Glu Thr Pro Leu Asn
20 25 30
Gln Glu Ser Ala Arg Lys Ser Glu Pro Pro Ala Pro Val Arg Arg Gln
35 40 45
Ser Tyr Ser Ser Thr Ser Arg Gly Ile Ser Val Thr Lys Lys Thr His
50 55 60
Thr Ser Gln Ile Glu Ile Ile Pro Cys Lys Ile Cys Gly Asp Lys Ser
65 70 75 80
Ser Gly Ile His Tyr Gly Val Ile Thr Cys Glu Gly Cys Lys Gly Phe
85 90 95
Phe Arg Arg Ser Gln Gln Ser Asn Ala Thr Tyr Ser Cys Pro Arg Gln
100 105 110
Lys Asn Cys Leu Ile Asp Arg Thr Ser Arg Asn Arg Cys Gln His Cys
115 120 125
Arg Leu Gln Lys Cys Leu Ala Val Gly Met Ser Arg Asp Ala Val Lys
130 135 140
Phe Gly Arg Met Ser Lys Lys Gln Arg Asp Ser Leu Tyr Ala Glu Val
145 150 155 160
Gln Lys His Arg Met Gln Gln Gln Gln Arg Asp His Gln Gln Gln Pro
165 170 175
Gly Glu Ala Glu Pro Leu Thr Pro Thr Tyr Asn Ile Ser Ala Asn Gly
180 185 190
Leu Thr Glu Leu His Asp Asp Leu Ser Asn Tyr Ile Asp Gly His Thr
195 200 205
Pro Glu Gly Ser Lys Ala Asp Ser Ala Val Ser Ser Phe Tyr Leu Asp
210 215 220
Ile Gln Pro Ser Pro Asp Gln Ser Gly Leu Asp Ile Asn Gly Ile Lys
225 230 235 240
Pro Glu Pro Ile Cys Asp Tyr Thr Pro Ala Ser Gly Phe Phe Pro Tyr
245 250 255
Cys Ser Phe Thr Asn Gly Glu Thr Ser Pro Thr Val Ser Met Ala Glu
260 265 270
Leu Glu His Leu Ala Gln Asn Ile Ser Lys Ser His Leu Glu Thr Cys
275 280 285
Gln Tyr Leu Arg Glu Glu Leu Gln Gln Ile Thr Trp Gln Thr Phe Leu
290 295 300
Gln Glu Glu Ile Glu Asn Tyr Gln Asn Lys Gln Arg Glu Val Met Trp
305 310 315 320
Gln Leu Cys Ala Ile Lys Ile Thr Glu Ala Ile Gln Tyr Val Val Glu
325 330 335
Phe Ala Lys Arg Ile Asp Gly Phe Met Glu Leu Cys Gln Asn Asp Gln
340 345 350
Ile Val Leu Leu Lys Ala Gly Ser Leu Glu Val Val Phe Ile Arg Met
355 360 365
Cys Arg Ala Phe Asp Ser Gln Asn Asn Thr Val Tyr Phe Asp Gly Lys
370 375 380
Tyr Ala Ser Pro Asp Val Phe Lys Ser Leu Gly Cys Glu Asp Phe Ile
385 390 395 400
Ser Phe Val Phe Glu Phe Gly Lys Ser Leu Cys Ser Met His Leu Thr
405 410 415
Glu Asp Glu Ile Ala Leu Phe Ser Ala Phe Val Leu Met Ser Ala Asp
420 425 430
Arg Ser Trp Leu Gln Glu Lys Val Lys Ile Glu Lys Leu Gln Gln Lys
435 440 445
Ile Gln Leu Ala Leu Gln His Val Leu Gln Lys Asn His Arg Glu Asp
450 455 460
Gly Ile Leu Thr Lys Leu Ile Cys Lys Val Ser Thr Leu Arg Ala Leu
465 470 475 480
Cys Gly Arg His Thr Glu Lys Leu Met Ala Phe Lys Ala Ile Tyr Pro
485 490 495
Asp Ile Val Arg Leu His Phe Pro Pro Leu Tyr Lys Glu Leu Phe Thr
500 505 510
Ser Glu Phe Glu Pro Ala Met Gln Ile Asp Gly
515 520
Claims (4)
1. a kind of nuclear receptor ROR α is preparing the application in heart failure resistance drug.
2. application according to claim 1, it is characterised in that: the nuclear receptor ROR α is nuclear receptor ROR α 1.
3. application according to claim 2, it is characterised in that: the transcript sequence such as SEQ of the nuclear receptor ROR α 1
Shown in ID NO.1.
4. application according to claim 2, it is characterised in that: the amino acid sequence such as SEQ of the nuclear receptor ROR α 1
Shown in ID NO.2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810909723.1A CN108939048A (en) | 2018-08-10 | 2018-08-10 | Nuclear receptor ROR α is preparing the application in heart failure resistance drug |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810909723.1A CN108939048A (en) | 2018-08-10 | 2018-08-10 | Nuclear receptor ROR α is preparing the application in heart failure resistance drug |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108939048A true CN108939048A (en) | 2018-12-07 |
Family
ID=64469277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810909723.1A Pending CN108939048A (en) | 2018-08-10 | 2018-08-10 | Nuclear receptor ROR α is preparing the application in heart failure resistance drug |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108939048A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113436741A (en) * | 2021-07-16 | 2021-09-24 | 四川大学华西医院 | Lung cancer recurrence prediction method based on tissue specific enhancer region DNA methylation |
CN114848795A (en) * | 2021-02-03 | 2022-08-05 | 四川大学 | Application of RORa protein and agonist thereof in preparation of anti-aging drugs |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104011069A (en) * | 2011-08-01 | 2014-08-27 | 塔夫茨医学中心有限公司 | Treatment of heart failure and related conditions |
-
2018
- 2018-08-10 CN CN201810909723.1A patent/CN108939048A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104011069A (en) * | 2011-08-01 | 2014-08-27 | 塔夫茨医学中心有限公司 | Treatment of heart failure and related conditions |
Non-Patent Citations (5)
Title |
---|
BEN HE等: "The nuclear melatonin receptor RORα is a novel endogenous defender against myocardial ischemia/reperfusion injury", 《J PINEAL RES》 * |
LI H等: "《GenBank》", 31 July 2018 * |
林嘉琛等: "视黄酸相关孤儿核受体RORα在脂质代谢调控中的作用", 《生理科学进展 》 * |
柴文等: "孤儿核受体RORs的病理生理作用", 《生理科学进展》 * |
石莺等: "孤核受体RORA的研究进展", 《国际病理科学与临床杂志》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114848795A (en) * | 2021-02-03 | 2022-08-05 | 四川大学 | Application of RORa protein and agonist thereof in preparation of anti-aging drugs |
CN114848795B (en) * | 2021-02-03 | 2023-04-14 | 四川大学 | Application of RORa protein and its agonist in the preparation of anti-aging medicine |
CN113436741A (en) * | 2021-07-16 | 2021-09-24 | 四川大学华西医院 | Lung cancer recurrence prediction method based on tissue specific enhancer region DNA methylation |
CN113436741B (en) * | 2021-07-16 | 2023-02-28 | 四川大学华西医院 | Lung cancer recurrence prediction method based on tissue specific enhancer region DNA methylation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Huynh et al. | Coenzyme Q 10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes | |
Kitahara et al. | High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice | |
Stansfield et al. | Periostin is a novel factor in cardiac remodeling after experimental and clinical unloading of the failing heart | |
CN111494605B (en) | Medical application of CREG protein in preventing or treating doxorubicin myocardial injury | |
TWI588153B (en) | Polypeptides, nucleic acid molecule encoding polypeptides, and uses of polypeptides | |
US20240016769A1 (en) | Method for preparing compound or biological drug enhancing CNPase activity for treating heart diseases | |
Shang et al. | Elevated β1-adrenergic receptor autoantibody levels increase atrial fibrillation susceptibility by promoting atrial fibrosis | |
CN108939048A (en) | Nuclear receptor ROR α is preparing the application in heart failure resistance drug | |
WO2021073249A1 (en) | USE OF β-NMN IN PREPARATION OF DRUG FOR TREATING AND PREVENTING SEPSIS-INDUCED ORGAN DAMAGE | |
CN113817769B (en) | Construction method and application of heart failure animal model with reserved ejection fraction | |
CN114533853B (en) | Application of Ctrp15 in preparation of product for promoting angiogenesis and improving cardiac function related to ischemia | |
Zuo et al. | TAX1BP1 downregulation by STAT3 in cardiac fibroblasts contributes to diabetes-induced heart failure with preserved ejection fraction | |
Zhai et al. | Mechanism of multifunctional adaptor protein SHARPIN regulating myocardial fibrosis and how SNP mutation affect the prognosis of myocardial infarction | |
CN110339343B (en) | Application of nuclear receptor Rev-erb alpha in preparation of anti-sepsis cardiomyopathy medicines | |
Tsai et al. | B-type natriuretic peptide enhances fibrotic effects via matrix metalloproteinase-2 expression in the mouse atrium in vivo and in human atrial myofibroblasts in vitro | |
CN114558111A (en) | Medicine for inhibiting adipocyte differentiation and insulin resistance | |
JP2008536880A (en) | Function and use of the GPR39 gene in the mammalian central nervous system | |
CN111474364B (en) | Use of human RAB22A and related products | |
Lagoutte et al. | Procollagen C-Proteinase Enhancer 1 (PCPE-1) is a marker of myocardial fibrosis and impaired cardiac function in a murine model of pressure overload | |
JP6677455B2 (en) | Evaluation or selection method of hair growth inhibitor | |
WO2014119387A1 (en) | Composition for treating or diagnosing diastolic heart failure and utilization thereof | |
WO2006104136A1 (en) | Therapeutic agent for non-alcoholic fatty liver disease, and screening method for drug candidate compound for treatment or prevention of non-alcoholic fatty liver disease | |
CN113692284A (en) | Relaxin receptor 1 for the treatment and prevention of heart failure | |
Zhang et al. | Decreased Mrpl42 expression exacerbates myocardial ischemia and reperfusion injury by inhibiting mitochondrial translation | |
JP4904269B2 (en) | Methods for screening carnitine transporter agonists or antagonists and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181207 |
|
WD01 | Invention patent application deemed withdrawn after publication |